Cladribine Combined with Idarubicin and Ara-C (CLIA) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia

被引：10
|
作者：
Jain, Preetesh [1 ]
Kantarjian, Hagop M. [1 ]
Ravandi, Farhad [1 ]
Jabbour, Elias [1 ]
Daver, Naval [1 ]
Pemmaraju, Naveen [1 ]
DiNardo, Courtney D. [1 ]
Alvarado, Yesid [1 ]
Jain, Nitin [1 ]
Borthakur, Gautam [1 ]
Verstovsek, Srdan [1 ]
Ferrajoli, Alessandra [1 ]
Ohanian, Maro [1 ]
Konopleva, Marina [1 ]
Naqvi, Kiran [1 ]
Fitch, Tina [1 ]
Garcia-Manero, Guillermo [1 ]
Cortes, Jorge E. [1 ]
Estrov, Zeev [1 ]
Kadia, Tapan M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1639.1639
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1639
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Cladribine Combined with Idarubicin and High-Dose AraC (CLIA2) As a Frontline and Salvage Treatment for Young Patients (≤65 yrs) with Acute Myeloid Leukemia
    Alfayez, Mansour
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Konopleva, Marina Y.
    Daver, Naval G.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Bose, Prithviraj
    Andreeff, Michael
    Alvarado, Yesid
    Yilmaz, Musa E.
    Pemmaraju, Naveen
    Kornblau, Steven M.
    Estrov, Zeev E.
    Benton, Christopher B.
    Takahashi, Koichi
    Naqvi, Kiran
    Slack, Rebecca
    Islam, Rubiul
    Jabbour, Elias J.
    Cortes, Jorge E.
    Kadia, Tapan M.
    BLOOD, 2018, 132
  • [2] Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia
    Kadia, Tapan M.
    Ravandi, Farhad
    Molica, Matteo
    Bataller, Alex
    Borthakur, Gautam
    Daver, Naval
    Jabbour, Elias
    Dinardo, Courtney D.
    Pemmaraju, Naveen
    Jain, Nitin
    Ferrajoli, Alessandra
    Ylimaz, Musa
    Bose, Prithviraj
    Tidwell, Rebecca Slack
    Marx, Kayleigh R.
    Rausch, Caitlin R.
    Kanagal-Shamanna, Rashmi
    Wang, Sa
    Islam, Rabiul
    Champlin, Richard
    Shpall, Elizabeth
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1711 - 1720
  • [3] ARA-C, IDARUBICINE AND GEMTUZUMAB OZOGAMICIN AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
    Capria, S.
    Cardarelli, L.
    Trisolini, S. M.
    Cartoni, C.
    Minotti, C.
    Gianfelici, V
    Arleo, E.
    Santini, L.
    De Propris, M. S.
    Mancini, M.
    Martinelli, G.
    Foa, R.
    Meloni, G.
    HAEMATOLOGICA, 2008, 93 : S84 - S84
  • [4] Ara-C, Idarubicine and Gentuzumab Ozogamicin (AIM) as Salvage Treatment in Advanced Acute Myeloid Leukemia Patients
    Capria, Saveria
    Trisolini, Silvia Maria
    Minotti, Clara
    Stefanizzi, Caterina
    Cardarelli, Luisa
    Canichella, Martina
    Cartoni, Claudio
    Diverio, Daniela
    De Propris, Maria Stefania
    Mancini, Marco
    Micozzi, Alessandra
    Foa, Robin
    Meloni, Giovanna
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2012, 4 (01):
  • [5] SUCCESSFUL SALVAGE TREATMENT WITH CLOFARABINE AND CYTARABINE (ARA-C) IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Malato, A.
    Santoro, A.
    Felice, R.
    Magrin, S.
    Turri, D.
    Di Bella, R.
    Salemi, D.
    Acquaviva, F.
    Scime, R.
    Fabbiano, F.
    HAEMATOLOGICA, 2013, 98 : 31 - 31
  • [6] Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Russo, D
    Malagola, M
    Vivo, A
    Fiacchini, M
    Martinelli, G
    Piccaluga, PP
    Damiani, D
    Candoni, A
    Michielutti, A
    Castelli, M
    Testoni, N
    Ottaviani, E
    Rondoni, M
    Pricolo, G
    Mazza, P
    Zuffa, E
    Zaccaria, A
    Raspadori, D
    Bocchia, M
    Lauria, F
    Bonini, A
    Avanzini, P
    Gugliotta, L
    Visani, G
    Fanin, R
    Baccarani, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (02) : 172 - 179
  • [7] Amonafide and ara-C treatment for secondary acute myeloid leukemia (sAML)
    Erba, H. P.
    Rizzieri, D. A.
    O'Donnell, M. R.
    Lundberg, A. S.
    Ajami, A. M.
    Rampersad, A. D.
    Capizzi, R. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] HIGH-DOSE ARA-C AND IDARUBICIN FOR THE TREATMENT OF ADVANCED ACUTE LYMPHOCYTIC LEUKEMIA(ALL)
    AMADORI, S
    TESTI, AM
    MELONI, G
    SPIRITI, MAA
    PULSONI, A
    GROTTO, P
    LADOGANA, S
    LOIACONO, G
    MINIERO, R
    NESPOLI, L
    CARELLA, AM
    MANDELLI, F
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 210 - 210
  • [9] ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA
    JAGER, U
    LECHNER, K
    SCHWARZINGER, I
    BETTELHEIM, P
    BOGNAR, H
    GEISSLER, K
    HAAS, O
    HINTERBERGER, W
    KOS, M
    LEITHA, T
    NEUMANN, E
    PANZER, S
    POLLAK, C
    BLUT, 1986, 53 (03): : 145 - 145
  • [10] Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Reville, Patrick K.
    Kantarjian, Hagop
    Borthakur, Gautam
    Yilmaz, Musa
    Daver, Naval
    Short, Nicholas
    DiNardo, Courtney D.
    Kornblau, Steven M.
    Pemmaraju, Naveen
    Jain, Nitin
    Alvarado, Yesid
    Bose, Prithviraj
    Jabbour, Elias
    Chien, Kelly S.
    Abbas, Hussein A.
    Masarova, Lucia
    Wang, Sa A.
    Tidwell, Rebecca S. S.
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Konopleva, Marina
    Ravandi, Farhad
    Kadia, Tapan M.
    BLOOD, 2022, 140 : 1702 - 1704
12345